Virtual HIV pre-exposure prophylaxis outpatient service in the era of COVID-19.
Adolescent
Adult
Aged
Aged, 80 and over
Ambulatory Care
Anti-HIV Agents
/ administration & dosage
COVID-19
/ epidemiology
Drug Therapy, Combination
Emtricitabine
/ administration & dosage
Female
HIV Infections
/ prevention & control
Humans
Ireland
/ epidemiology
Male
Middle Aged
Pandemics
Pre-Exposure Prophylaxis
SARS-CoV-2
/ isolation & purification
Tenofovir
/ administration & dosage
Human immunodeficiency virus
antiretroviral therapy
prevention
Journal
International journal of STD & AIDS
ISSN: 1758-1052
Titre abrégé: Int J STD AIDS
Pays: England
ID NLM: 9007917
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
pubmed:
15
10
2020
medline:
30
1
2021
entrez:
14
10
2020
Statut:
ppublish
Résumé
In the midst of the COVID-19 pandemic, health care providers have had to rapidly change how they deliver care to patients. We discuss how we are delivering a virtual HIV pre-exposure prophylaxis (PrEP) service during this time; challenges faced; challenges expected and goals for the coming months.
Identifiants
pubmed: 33050787
doi: 10.1177/0956462420961951
pmc: PMC7817984
doi:
Substances chimiques
Anti-HIV Agents
0
Tenofovir
99YXE507IL
Emtricitabine
G70B4ETF4S
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
100-103Références
Lancet HIV. 2020 Jul;7(7):e460
pubmed: 32464106